



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Manfred Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	1	of	1	Attorney Docket Number	01017/40451C

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear ⁶


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
P31		Official Communication relating to an Opposition in EP Application No. 99 100 703.0.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/1/07
--------------------	--	-----------------	--------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	8	Attorney Docket Number	01017/40451C
-------	---	----	---	------------------------	--------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
VJS	A5	08/478,995	N/A	Lauffler, Leander et al.	
	A6	2003/064480	04-03-2003	Lauffler, Leander et al.	
	A7	4,593,002	01-11-1982	Dulbecco	
	A8	4,675,285	09-19-1984	Clark et al.	
	A9	4,729,326	03-08-1988	Richter	
	A10	4,769,326	09-06-1988	Rutler	
	A11	4,894,439	01-16-1990	Dorin et al.	
	A12	4,912,044	03-27-1990	Jacob et al.	
	A13	4,935,233	06-19-1990	Bell et al.	
	A14	4,963,354	10-06-1990	Shepard et al.	
	A15	4,965,271	10-23-1990	Mandell et al.	
	A16	5,055,447	10-08-1991	Palladino et al.	
	A17	5,073,627	12-17-1991	Curtis et al.	
	A18	5,075,222	12-24-1991	Hannum et al.	
	A19	5,098,702	03-24-1992	Zimmerman et al.	
	A20	5,098,833	03-24-1992	Lasky et al.	
	A21	5,118,500	06-02-1992	Hanel et al.	
	A22	5,136,021	08-04-1992	Dembinski et al.	
	A23	5,155,027	10-13-1992	Sledziewski et al.	
	A24	5,211,395	06-29-1993	Gero	
	A25	5,211,945	05-18-1993	Wallach et al.	
	A26	5,225,538	07-06-1993	Capon et al.	
	A27	5,258,498	11-02-1993	Huston et al.	
	A28	5,264,416	11-23-1993	Park et al.	
	A29	5,270,038	12-14-1993	Klimpel et al.	
	A30	5,336,603	08-09-1994	Capon et al.	
	A31	5,350,683	09-27-1994	Sims et al.	
	A32	5,359,032	10-25-1994	Dayer et al.	
	A33	5,447,851	09-05-1995	Beutler et al.	
	A34	5,455,165	10-03-1995	Capon et al.	
	A35	5,478,925	12-26-1995	Wallach et al.	
	A36	5,512,544	04-30-1996	Wallach et al.	
	A37	5,514,582	05-07-1996	Capon et al.	
	A38	5,599,905	02-04-1997	Mosley et al.	
	A39	5,605,690	02-25-1997	Jacobs et al.	
	A40	5,610,279	03-11-1997	Brockhaus et al.	
	A41	5,633,145	05-27-1997	Feldmann et al.	
	A42	5,639,597	06-17-1997	Lauffer et al.	
	A43	5,695,953	12-09-1997	Wallach et al.	
	A44	5,705,364	01-06-1998	Etcheverry et al.	
	A45	5,712,155	01-27-1998	Smith et al.	
	A46	5,721,121	02-24-1998	Etcheverry et al.	
	A47	5,808,029	09-15-1998	Brockhaus et al.	
	A48	5,811,261	09-22-1998	Wallach et al.	
	A49	5,863,786	01-26-1999	Feldmann et al.	
	A50	5,945,397	08-31-1999	Smith et al.	

Examiner Signature		Date Considered	3/11/07
--------------------	--	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	8	Attorney Docket Number	01017/40451C
-------	---	----	---	------------------------	--------------

131	A51	5,981,701	11-09-1999	Wallach et al.	
	A52	6,143,866	11-07-2000	Brewer et al.	
	A53	6,165,476	12-26-2000	Strom et al.	
	A54	6,201,105	03-13-2001	Smith et al.	
	A55	6,221,675	04-24-2001	Hauptmann et al.	
	A56	6,271,346	08-07-2001	Hauptmann et al.	
	A57	6,294,352	09-25-2001	Hauptmann et al.	
	A58	6,541,610	04-01-2003	Smith	
	A59	6,541,620	04-01-2003	Brewer et al.	
	A60	6,572,852	06-03-2003	Smith et al.	
↓	A61	RE 36,755	06-27-2000	Smith et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY			
131	B13	AU 58976	01-24-1991	Synergen, Inc.		
	B14	EP 120694	10-03-1984	Boss et al.		
	B15	EP 227110	07-01-1987	Satoshi et al.		
	B16	EP 230574	08-05-1987	Ruddle		
	B17	EP 269455	06-01-1988	Ikeyama et al.		
	B18	EP 314317	05-03-1989	Capon et al.		
	B19	EP 325262	07-26-1989	Seed		
	B20	EP 414178	02-27-1991	Seed		
131	B21	EP 417563	03-20-1991	Wallach et al.		
	B22	EP 460846	12-11-1991	Sims et al.		
	B23	EP 471701	02-26-1992	Lemerle et al.		
131	B24	EP 526452	02-10-1993	Capon et al.		
	B25	EP 526905	02-10-1993	Wallach et al.		
	B26	EP 568925	11-10-1993	Wallach et al.		
	B27	EP 606869	07-20-1994	Wallach et al.		
	B28	GB 2,218,101A	10-08-1989	Dayer and Seckinger		
	B29	GB 2 246 569	02-05-1992	Feldman et al.		
	B30	JP 02-154695	06-14-1990	Wallach et al.		
131	B31	JP 01-293024	12-24-1986	Yojiro et al.		
131	B32	WO 91/02078	02-21-1991	Rathjen et al.		
	B33	WO 91/08298	12-13-1991	Capon et al.		
	B34	WO 91/17184	11-14-1991	Carter		
	B35	WO 92/08495	05-29-1992	Gillies		
	B36	WO 92/13095	08-06-1992	Carmichael et al.		
	B37	WO 93/07863	04-29-1993	Mullarkey		
	B38	WO 93/19777	10-14-1993	Smith		
131	B39	WO 94/06476	03-31-1994	Smith et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/11/03
--------------------	--	-----------------	---------

crossed out document
 crossed out copy license
 note 1
 note 2
 note 3
 note 4
 note 5
 note 6
 note 7
 note 8
 note 9
 note 10
 note 11
 note 12
 note 13
 note 14
 note 15
 note 16
 note 17
 note 18
 note 19
 note 20
 note 21
 note 22
 note 23
 note 24
 note 25
 note 26
 note 27
 note 28
 note 29
 note 30
 note 31
 note 32
 note 33
 note 34
 note 35
 note 36
 note 37
 note 38
 note 39
 note 40
 note 41
 note 42
 note 43
 note 44
 note 45
 note 46
 note 47
 note 48
 note 49
 note 50
 note 51
 note 52
 note 53
 note 54
 note 55
 note 56
 note 57
 note 58
 note 59
 note 60
 note 61
 note 62
 note 63
 note 64
 note 65
 note 66
 note 67
 note 68
 note 69
 note 70
 note 71
 note 72
 note 73
 note 74
 note 75
 note 76
 note 77
 note 78
 note 79
 note 80
 note 81
 note 82
 note 83
 note 84
 note 85
 note 86
 note 87
 note 88
 note 89
 note 90
 note 91
 note 92
 note 93
 note 94
 note 95
 note 96
 note 97
 note 98
 note 99
 note 100
 note 101
 note 102
 note 103
 note 104
 note 105
 note 106
 note 107
 note 108
 note 109
 note 110
 note 111
 note 112
 note 113
 note 114
 note 115
 note 116
 note 117
 note 118
 note 119
 note 120
 note 121
 note 122
 note 123
 note 124
 note 125
 note 126
 note 127
 note 128
 note 129
 note 130
 note 131
 note 132
 note 133
 note 134
 note 135
 note 136
 note 137
 note 138
 note 139
 note 140
 note 141
 note 142
 note 143
 note 144
 note 145
 note 146
 note 147
 note 148
 note 149
 note 150
 note 151
 note 152
 note 153
 note 154
 note 155
 note 156
 note 157
 note 158
 note 159
 note 160
 note 161
 note 162
 note 163
 note 164
 note 165
 note 166
 note 167
 note 168
 note 169
 note 170
 note 171
 note 172
 note 173
 note 174
 note 175
 note 176
 note 177
 note 178
 note 179
 note 180
 note 181
 note 182
 note 183
 note 184
 note 185
 note 186
 note 187
 note 188
 note 189
 note 190
 note 191
 note 192
 note 193
 note 194
 note 195
 note 196
 note 197
 note 198
 note 199
 note 200
 note 201
 note 202
 note 203
 note 204
 note 205
 note 206
 note 207
 note 208
 note 209
 note 210
 note 211
 note 212
 note 213
 note 214
 note 215
 note 216
 note 217
 note 218
 note 219
 note 220
 note 221
 note 222
 note 223
 note 224
 note 225
 note 226
 note 227
 note 228
 note 229
 note 230
 note 231
 note 232
 note 233
 note 234
 note 235
 note 236
 note 237
 note 238
 note 239
 note 240
 note 241
 note 242
 note 243
 note 244
 note 245
 note 246
 note 247
 note 248
 note 249
 note 250
 note 251
 note 252
 note 253
 note 254
 note 255
 note 256
 note 257
 note 258
 note 259
 note 260
 note 261
 note 262
 note 263
 note 264
 note 265
 note 266
 note 267
 note 268
 note 269
 note 270
 note 271
 note 272
 note 273
 note 274
 note 275
 note 276
 note 277
 note 278
 note 279
 note 280
 note 281
 note 282
 note 283
 note 284
 note 285
 note 286
 note 287
 note 288
 note 289
 note 290
 note 291
 note 292
 note 293
 note 294
 note 295
 note 296
 note 297
 note 298
 note 299
 note 300
 note 301
 note 302
 note 303
 note 304
 note 305
 note 306
 note 307
 note 308
 note 309
 note 310
 note 311
 note 312
 note 313
 note 314
 note 315
 note 316
 note 317
 note 318
 note 319
 note 320
 note 321
 note 322
 note 323
 note 324
 note 325
 note 326
 note 327
 note 328
 note 329
 note 330
 note 331
 note 332
 note 333
 note 334
 note 335
 note 336
 note 337
 note 338
 note 339
 note 340
 note 341
 note 342
 note 343
 note 344
 note 345
 note 346
 note 347
 note 348
 note 349
 note 350
 note 351
 note 352
 note 353
 note 354
 note 355
 note 356
 note 357
 note 358
 note 359
 note 360
 note 361
 note 362
 note 363
 note 364
 note 365
 note 366
 note 367
 note 368
 note 369
 note 370
 note 371
 note 372
 note 373
 note 374
 note 375
 note 376
 note 377
 note 378
 note 379
 note 380
 note 381
 note 382
 note 383
 note 384
 note 385
 note 386
 note 387
 note 388
 note 389
 note 390
 note 391
 note 392
 note 393
 note 394
 note 395
 note 396
 note 397
 note 398
 note 399
 note 400
 note 401
 note 402
 note 403
 note 404
 note 405
 note 406
 note 407
 note 408
 note 409
 note 410
 note 411
 note 412
 note 413
 note 414
 note 415
 note 416
 note 417
 note 418
 note 419
 note 420
 note 421
 note 422
 note 423
 note 424
 note 425
 note 426
 note 427
 note 428
 note 429
 note 430
 note 431
 note 432
 note 433
 note 434
 note 435
 note 436
 note 437
 note 438
 note 439
 note 440
 note 441
 note 442
 note 443
 note 444
 note 445
 note 446
 note 447
 note 448
 note 449
 note 450
 note 451
 note 452
 note 453
 note 454
 note 455
 note 456
 note 457
 note 458
 note 459
 note 460
 note 461
 note 462
 note 463
 note 464
 note 465
 note 466
 note 467
 note 468
 note 469
 note 470
 note 471
 note 472
 note 473
 note 474
 note 475
 note 476
 note 477
 note 478
 note 479
 note 480
 note 481
 note 482
 note 483
 note 484
 note 485
 note 486
 note 487
 note 488
 note 489
 note 490
 note 491
 note 492
 note 493
 note 494
 note 495
 note 496
 note 497
 note 498
 note 499
 note 500
 note 501
 note 502
 note 503
 note 504
 note 505
 note 506
 note 507
 note 508
 note 509
 note 510
 note 511
 note 512
 note 513
 note 514
 note 515
 note 516
 note 517
 note 518
 note 519
 note 520
 note 521
 note 522
 note 523
 note 524
 note 525
 note 526
 note 527
 note 528
 note 529
 note 530
 note 531
 note 532
 note 533
 note 534
 note 535
 note 536
 note 537
 note 538
 note 539
 note 540
 note 541
 note 542
 note 543
 note 544
 note 545
 note 546
 note 547
 note 548
 note 549
 note 550
 note 551
 note 552
 note 553
 note 554
 note 555
 note 556
 note 557
 note 558
 note 559
 note 560
 note 561
 note 562
 note 563
 note 564
 note 565
 note 566
 note 567
 note 568
 note 569
 note 570
 note 571
 note 572
 note 573
 note 574
 note 575
 note 576
 note 577
 note 578
 note 579
 note 580
 note 581
 note 582
 note 583
 note 584
 note 585
 note 586
 note 587
 note 588
 note 589
 note 590
 note 591
 note 592
 note 593
 note 594
 note 595
 note 596
 note 597
 note 598
 note 599
 note 600
 note 601
 note 602
 note 603
 note 604
 note 605
 note 606
 note 607
 note 608
 note 609
 note 610
 note 611
 note 612
 note 613
 note 614
 note 615
 note 616
 note 617
 note 618
 note 619
 note 620
 note 621
 note 622
 note 623
 note 624
 note 625
 note 626
 note 627
 note 628
 note 629
 note 630
 note 631
 note 632
 note 633
 note 634
 note 635
 note 636
 note 637
 note 638
 note 639
 note 640
 note 641
 note 642
 note 643
 note 644
 note 645
 note 646
 note 647
 note 648
 note 649
 note 650
 note 651
 note 652
 note 653
 note 654
 note 655
 note 656
 note 657
 note 658
 note 659
 note 660
 note 661
 note 662
 note 663
 note 664
 note 665
 note 666
 note 667
 note 668
 note 669
 note 670
 note 671
 note 672
 note 673
 note 674
 note 675
 note 676
 note 677
 note 678
 note 679
 note 680
 note 681
 note 682
 note 683
 note 684
 note 685
 note 686
 note 687
 note 688
 note 689
 note 690
 note 691
 note 692
 note 693
 note 694
 note 695
 note 696
 note 697
 note 698
 note 699
 note 700
 note 701
 note 702
 note 703
 note 704
 note 705
 note 706
 note 707
 note 708
 note 709
 note 710
 note 711
 note 712
 note 713
 note 714
 note 715
 note 716
 note 717
 note 718
 note 719
 note 720
 note 721
 note 722
 note 723
 note 724
 note 725
 note 726
 note 727
 note 728
 note 729
 note 730
 note 731
 note 732
 note 733
 note 734
 note 735
 note 736
 note 737
 note 738
 note 739
 note 740
 note 741
 note 742
 note 743
 note 744
 note 745
 note 746
 note 747
 note 748
 note 749
 note 750
 note 751
 note 752
 note 753
 note 754
 note 755
 note 756
 note 757
 note 758
 note 759
 note 760
 note 761
 note 762
 note 763
 note 764
 note 765
 note 766
 note 767
 note 768
 note 769
 note 770
 note 771
 note 772
 note 773
 note 774
 note 775
 note 776
 note 777
 note 778
 note 779
 note 780
 note 781
 note 782
 note 783
 note 784
 note 785
 note 786
 note 787
 note 788
 note 789
 note 790
 note 791
 note 792
 note 793
 note 794
 note 795
 note 796
 note 797
 note 798
 note 799
 note 800
 note 801
 note 802
 note 803
 note 804
 note 805
 note 806
 note 807
 note 808
 note 809
 note 810
 note 811
 note 812
 note 813
 note 814
 note 815
 note 816
 note 817
 note 818
 note 819
 note 820
 note 821
 note 822
 note 823
 note 824
 note 825
 note 826
 note 827
 note 828
 note 829
 note 830
 note 831
 note 832
 note 833
 note 834
 note 835
 note 836
 note 837
 note 838
 note 839
 note 840
 note 841
 note 842
 note 843
 note 844
 note 845
 note 846
 note 847
 note 848
 note 849
 note 850
 note 851
 note 852
 note 853
 note 854
 note 855
 note 856
 note 857
 note 858
 note 859
 note 860
 note 861
 note 862
 note 863
 note 864
 note 865
 note 866
 note 867
 note 868
 note 869
 note 870
 note 871
 note 872
 note 873
 note 874
 note 875
 note 876
 note 877
 note 878
 note 879
 note 880
 note 881
 note 882
 note 883
 note 884
 note 885
 note 886
 note 887
 note 888
 note 889
 note 890
 note 891
 note 892
 note 893
 note 894
 note 895
 note 896
 note 897
 note 898
 note 899
 note 900
 note 901
 note 902
 note 903
 note 904
 note 905
 note 906
 note 907
 note 908<br



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperless Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	3	of	8	Attorney Docket Number	01017/40451C

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MJS	C31	ABRAHAM et al., p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: $\Delta\Delta\Delta\Delta$ JAMA, 277:1531-1538 (1997)	
	C32	ABRAHAM et al., Lenercept (p55 Tumor Necrosis Factor Receptor Fusion Protein) In Severe Sepsis and Early Septic Shock: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial With 1,342 Patients, Crit Care Med., 29:503-510 (2001)	
	C33	AGGARWAL et al., Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by γ -Interferon, Nature, 318:665-667 (1985)	
	C34	AGGARWAL et al., Induction of Receptors for Tumor Necrosis Factor- α by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response, J. Biol. Chem., 262:10000-10007 (1987)	
	C35	AGGARWAL et al., Human tumour necrosis factors: structure and receptor interactions, in Tumor necrosis factor and related cytotoxins, pp.. 39-51, (Ciba Foundation symposium 131), Wiley, Chichester (1987)	
	C36	ARENZANA-SEISDEDOS et al., Immunoregulatory Mediators in the Pathogenesis of Rheumatoid Arthritis, Scand. J. Rheumatol., Supplément 66:13-17 (1987)	
	C37	ARUFFO et al., Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System, Proc. Natl. Acad. Sci. USA, 84:8573-8577 (1987).	
	C38	ASHKENAZI et al., Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin, Proc. Natl. Acad. Sci., U.S.A. 88:10535-10539 (1991)	
	C39	AYALA, Modern Genetics, Benjamin/Cummings, Publ. Co., Menlo Park CA, p. 45, (1980)	
	C40	BAGLIONI et al., Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition, J. Biol. Chem., 260:13395-13397 (1985)	
	C41	BENJAMINI et al., Antibody Structure, in Immunology: A Short Course, 3rd ed., Wiley-Liss New York, 61-69 (1996)	
	C42	BRANELLEC et al., TNF: Antitumoral Agent at the Border Lines of Immunity and Inflammation, Path. Biol., 39:230-239 (1991)	
	C43	BROCKHAUS et al., Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies, Proc. Natl. Acad. Sci. USA, 87:3127-3131 (1990)	
	C44	CARTER et al., Purification, Cloning, Expression and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein, Nature, 344:633-638 (1990)	
	C45	CARPENTER et al., Epidermal Growth Factor, J. Biol. Chem., 265:7709-7712 (1990)	
	C46	CARPENTER, Receptors For Epidermal Growth Factor And Other Polypeptide Mitogens, Ann. Rev. Biochem., 56:881-914 (1987)	
	C47	CASADEI et al., Expression and Secretion of Aequorin as a Chimeric Antibody by Means of a Mammalian Expression Vector, Proc. Natl. Acad. Sci., U.S.A. 87:2047-2051 (1990)	
	C48	COFFMAN et al., The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation, Immunol. Rev., 102:5-28 (1988)	
	C49	CREASEY et al., A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated With Cytotoxicity, Proc. Natl. Acad. Sci. USA, 84:3293-3297 (1987)	

Examiner Signature		Date Considered	3/10/07
--------------------	--	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	8	Attorney Docket Number	01017/40451C
-------	---	----	---	------------------------	--------------

	C50	DAYER, Chronic Inflammatory Joint Diseases: Natural Inhibitors of Interleukin 1 and Tumor Necrosis Factor α , J. Rheumatol., 18 (Suppl. 27): 71-75 (1991)
	C51	DOWER et al., Human Cytokine Receptors, J. Clin. Immunol., 10:289-299 (1990)
	C52	EISENBERG et al., Primary Structure and Functional Expression From Complementary DNA of a Human Interleukin-1 Receptor Antagonist, Nature, 343:341-346 (1990)
	C53	ELLISON et al., The Nucleotide Sequence of A Human Immunoglobulin Cy1 Gene, Nucleic Acids Res. 10(13): 4071-79 (1982)
	C54	ESMON, The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation, J. Biol. Chem., 264:4743-4746 (1989)
	C55	European Search Report for EP 97 12 0664, dated 3/9/98
	C56	FELL et al., Genetic Construction And Characterization Of A Fusion Protein Consisting Of A Chimeric F(ab') With Specificity For Carcinomas And Human IL-2, J. Immunol., 146:2446-2452 (1991)
	C57	FERNANDEZ-BOTRAN et al., A Soluble, High-Affinity, Interleukin-4-Binding Protein is Present in the Biological Fluids of Mice, Proc. Natl. Acad. Sci., 87:4202-4206 (1990)
	C58	FERNANDEZ-BOTRAN, Soluble Cytokine Receptors: Their Role in Immunoregulation, The FASEB Journal, 5:2567-2574 (1991)
	C59	FERRANTE et al., Inhibition of Tumour Necrosis Factor Alpha (TNF- α)-Induced Neutrophil Respiratory Burst by a TNF Inhibitor, Immunology, 72:440-442 (1991)
	C60	FISHER et al., Cloning And Expression Of Human Tissue Factor cDNA, Thrombosis Research, 48:89-99 (1987)
	C61	FISHER et al., Treatment of Septic Shock with the Tumor Necrosis Factor Receptor: Fc Fusion Protein, New Eng. J. Med., 334:1697-1702 (1996)
	C62	FOLEY et al., An Inhibitor of the Toxicity of Tumour Necrosis Factor in the Serum of Patients With Sarcoidosis, Tuberculosis and Crohn's Disease, Clin. Exp. Immunol., 80:395-399 (1990)
	C63	FOMSGAARD et al., Preliminary Study on Treatment of Septic Shock Patients With Antilipopolysaccharide IgG from Blood Donors, Scand. J. Infect. Dis., 21:697-708 (1989)
	C64	GARCIA et al., High Sensitivity of Transgenic Mice Expressing Soluble TNFR1 Fusion Protein to Mycobacterial Infections: Synergistic Action of TNF and IFN- γ in the Differentiation of Protective Granulomas, Eur. J. Immunol., 27:3182-3190 (1997)
	C65	GASCOIGNE et al., Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein, Proc. Natl. Acad. Sci USA, 84:2936-2940 (1987)
	C66	GEHR et al., Both Tumor Necrosis Factor Receptor Types Mediate Proliferative Signals In Human Mononuclear Cell Activation, J. Immunol., 149:911-917 (1992).
	C67	GILLIES et al., Targeting Human Cytotoxic T Lymphocytes To Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells, J. Immunol., 144:1067-1071 (1991)
	C68	GOODMAN, Identification of Antigenic Determinants, in Basic & Clinical Immunol., 24-25 (1982)
	C69	GOODMAN, Immunogenicity & Antigenic Specificity, in Basic & Clinical Immunol., 101-108 (1991)
	C70	GOODWIN et al., Molecular cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor, Molecular and Cellular Biology, 11:3020-3026 (1991)
	C71	GRAY et al., Cloning and Expression of cDNA for Human Lymphotoxin, a Lymphokine With Tumour Necrosis Activity, Nature, 312:721-724 (1984)
	C72	GRAY et al., Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein, Proc. Natl. Acad. Sci. 87: 7380-84 (1990)
	C73	GRUNDMANN et al., Characterization of cDNA Coding for Human Factor XIIIa, Proc. Natl. Acad. Sci. USA, 83:8024-8028 (1986)
	C74	HAAK-FRENDSCHO et al., Inhibition of TNF by a TNF Receptor Immunoadhesin, J. Immunol., 152:1347-1353 (1994)

Examiner Signature		Date Considered	3/11/07
--------------------	--	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet:	5	of	8	Attorney Docket Number	01017/40451C

(m)	C75	HANNUM et al., Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor, Nature, 343:336-340 (1990)	
	C76	HEFLIN et al., Prevention by Granulocyte Depletion of Increased Vascular Permeability of Sheep Lung Following Endotoxemia, J. Clin. Invest., 68:1253-1260 (1981).	
	C77	HELLER et al., Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected With Epstein-Barr Virus Shuttle Vector cDNA Libraries, J. Biol. Chem., 265:5708-5717 (1990)	
	C78	HELLER et al., Amplified Expression of the Tumor Necrosis Factor Receptor in Lymphoblastoid Cells Transfected with HeLa Cell-CDNA Expression Abstract WA 142, Napa Valley Conference 1989	
	C79	HIMMLER et al., Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein, DNA and Cell Biology, 9:705-715 (1990)	
	C80	HOBART, The Immune System: A Course on the Molecular and Cellular Basis of immunity, Blackwell Scientific Pubs, Page 7 (1975)	
	C81	HOLTMANN et al., Down Regulation of the Receptors For Tumor Necrosis Factor By Interleukin 1 and 4 β -Phorbol-12-Myristate-13-Acetate, J. Immunol., 139:1161-1167 (1987).	
	C82	HSU et al., Differential Expression and Ligand Binding Properties of Tumor Necrosis Factor Receptor Chimeric Mutants, J. Biol. Chem., 268:16430-16436 (1992)	
	C83	IDZERDA et al., Human Interleukin 4 Receptor Confers Biological Responsiveness And Defines A Novel Receptor Superfamily, J. Exp. Med., 171:861-873 (1990)	
	C84	IMAMURA et al., Expression Of Tumor Necrosis Factor Receptors On Human Monocytes And Internalization Of Receptor Bound Ligand, J. Immunol., 139:2989-2992 (1987)	
	C85	ISHIKURA et al., Differential Biologic Effects Resulting From Bimodal Binding of Recombinant Human Tumor Necrosis Factor to Myeloid Leukemia Cells, Blood, 73:419-424 (1989)	
	C86	ISRAEL et al., Binding Of Human TNF- α To High-Affinity Cell Surface Receptors: Effect Of IFN, Immunology Letters, 12:217-224 (1986)	
	C87	JACOBS et al., Pharmacokinetic Parameters and Biodistribution of Soluble Cytokine Receptors, International Review of Experimental Pathology, 34B:123-135 (1993)	
	C88	JONES et al., Structure of Tumour Necrosis Factor, Nature, 338:225-228 (1989)	
	C89	KACZMARSKI et al., The Cytokine Receptor Superfamily, Blood Reviews, 5:193-203 (1991)	
	C90	KAUSHANSKY, Structure-Function Relationships of the Hematopoietic Growth Factors, Proteins: Structure, Function & Genetics, 12:1-9 (1992)	
	C91	KEEGAN et al., The Interleukin-4 Receptor: Signal Transduction by a Hematopoietin Receptor, Journal of Leukocyte Biology, 55:272-279 (1994)	
	C92	KEEGAN et al., Interleukin 4 Receptor: Signaling Mechanisms, Immunology Today, 15:423-432 (1994)	
	C93	KLEINAU et al., Importance of CD23 for Collagen-Induced Arthritis: Delayed Onset and Reduced Severity in CD23-Deficient Mice, J. Immunol., 162:4266-4270 (1999)	
	C94	KLINKERT et al., TNF- α Receptor Fusion Protein Prevents Experimental Auto-Immune Encephalomyelitis and Demyelination in Lewis Rats: an Overview, The Journal of Neuroimmunology, 72:163-168 (1997).	
	C95	KOHNO et al., A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor, Proc. Natl. Acad. Sci. USA, 87:8331-8335 (1990)	
	C96	KRUSE et al., Conversion of Human Interleukin-4 Into a High Affinity Antagonist by a Single Amino Acid Replacement, The EMBO Journal, 11:3237-3244 (1992)	
	C97	KULL et al., Cellular Receptor for 125 I-Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity, Proc. Natl. Acad. Sci. USA, 82:5756-5760 (1985)	
✓	C98	LANDOLFI, A Chimeric IL-2/Ig Molecule Possesses The Functional Activity Of Both Proteins, J. Immunol., 146:915-919 (1991)	

Examiner Signature			Date Considered	3/11/05
--------------------	--	--	-----------------	---------



PTO/SB/08a/b (08-03)


Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	6	of	8	Attorney Docket Number	01017/40451C

(b)	C99	LANGNER et al., Structural and Functional Analysis of a TNF Receptor-Immunoglobulin Fusion Protein, New Advances on Cytokines, 349-354 (1992)	
	C100	LEBERTHON et al., Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate, Cancer Research, 51:2694-2698 (1991)	
	C101	LESSLAUER et al., Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality, Eur. J. Immunol., 21:2883-2886 (1991)	
	C102	LIABAKK et al., A Rapid and Sensitive Immunoassay for Tumor Necrosis Factor Using Magnetic Monodisperse Polymer Particles, Journal of Immunological Methods, 134:253-259 (1990)	
	C103	LOETSCHER et al., Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock, Endotoxin Research Series, 2:455-462 (1993)	
	C104	LOETSCHER et al., Two distinct human TNF receptors: purification, molecular cloning and expression, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3 rd International Conference	
	C105	MALISZEWSKI et al., Cytokine Receptors And B Cell Functions: Recombinant Soluble Receptors Specifically Inhibit IL-1 and IL-4 Induced Cell Activities In Vitro, J. Immunol., 144:3028-3033 (1990)	
	C106	MOHLER et al., Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists, J. Immunol., 151:1548-1561 (1993)	
	C107	MORI et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 157:3178-3182 (1996)	
	C108	MORRISSEY et al., Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade, Cell, 50:129-135 (1987)	
	C109	MORRISON, In Vitro Antibodies: Strategies for Production and Application, Annu. Rev. Immunol., 10:239-265 (1992)	
	C110	MOSLEY et al., The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms, Cell, 59:335-348 (1989)	
	C111	NOPHAR et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, The EMBO Journal, 9:3269-3278 (1990)	
	C112	NOVOTNY et al., A Soluble, Single-Chain T-Cell Receptor Fragment Endowed With Antigen-Combining Properties, Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991)	
	C113	OKAYAMA et al., High-Efficiency Cloning of Full-Length cDNA, Molecular and Cellular Biology, 2:161-170 (1982)	
	C114	OKAYAMA et al., A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells, Molecular and Cellular Biology, 3:280-289 (1983)	
	C115	OLD, Tumor Necrosis Factor, 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 1-30 (1989)	
	C116	PABORSKY et al., Purification of Recombinant Human Tissue Factor, Biochemistry, 28:8072-8077 (1989)	
	C117	PARRILLO, Pathogenetic Mechanisms of Septic Shock, New Eng. J. Med., 328:1471-1477 (1993)	
	C118	PEETRE et al., A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids, Eur. J. Haematol. 41:414-419 (1988)	
	C119	PENNICA et al., Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin, Nature, 312:724-729 (1984).	
	C120	PEPPEL et al., Chimaeric TNF-Receptor - IgG Molecule Acts As Soluble Inhibitor Of TNF Mediated Cytotoxicity, J. Cell. Biochem., Supp. 15F:439 (1991)	

Examiner Signature		Date Considered	3/1/07
--------------------	--	-----------------	--------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

Application Number	08/444,791-Conf. #5613
Filing Date	May 19, 1995
First Named Inventor	Brockhaus
Art Unit	1644
Examiner Name	R. Schwadron, Ph.D.

Sheet

7 of 8

Attorney Docket Number

01017/40451C

PMS	C121	PIGUET et al., Evolution of Collagen Arthritis in Mice is Arrested by Treatment With Anti-Tumor Necrosis (TNF) Antibody or a Recombinant Soluble TNF Receptor, <i>Immunology</i> , 77 (4):510-514 (1992)
	C122	REDFIELD et al., Secondary Structure and Topology of Human Interleukin 4 in Solution, <i>Biochemistry</i> , 30:11029-11035 (1991)
	C123	RUBIN, Binding Receptor Characters Zako and Expression, and Intracellular Events. 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 94-96 (1989)
	C124	RUDDLE et al., An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis, <i>J. Exp. Med.</i> , 172:1193-1200 (1990)
	C125	RUTKA et al., The Effects of Human Recombinant Tumor Necrosis Factor on Glioma-Derived Cell Lines: Cellular Proliferation, Cytotoxicity, Morphological and Radioreceptor Studies, <i>Int. J. Cancer.</i> , 41:573-582 (1988)
	C126	SAXNE et al., Detection of Tumor Necrosis Factor α But Not Tumor Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum, <i>Arthritis & Rheumatism</i> , 31:1041-1045 (1988)
	C127	SCALLON et al., Functional Comparisons Of Different Tumour Necrosis Factor Receptor/IgG Fusion Proteins, <i>Cytokine</i> , 7:759-770 (1995)
	C128	SCARPATI et al., Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene, <i>Biochemistry</i> , 26:5234-5238 (1987)
	C129	SCHLEIFFENBAUM et al., The Tumor Necrosis Factor Receptor and Human Neutrophil Function, <i>J. Clin. Invest.</i> , 86:184-195 (1990)
	C130	SCHNEE et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, <i>Proc. Natl. Acad. Sci. USA</i> , 84:6904-6908 (1987)
	C131	SECKINGER et al., A Human Inhibitor Of Tumor Necrosis Factor α , <i>J. Exp. Med.</i> 167:1511-1516 (1988)
	C132	SHALABY et al., Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha, <i>Journal of Leukocyte Biology</i> , 41:196-204 (1987)
	C133	SHALABY et al., Binding and Regulation of Cellular Function by Monoclonal antibodies Against Human Tumor Necrosis Factor Receptors, <i>J. Exp. Med.</i> 172: 1517-1520 (1990)
	C134	SHEEHAN et al., Generation and Characterization of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors, <i>Journal of Immunology</i> , 142:3884-3893 (1989)
	C135	SHIN et al., Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-Like Growth Factor 1: Potential Applications for Cellular Targeting, <i>Proc. Natl. Acad. Sci.</i> , 87:5322-5326 (1990)
	C136	SIMS et al., cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily, <i>Science</i> , 241:585-589 (1988).
	C137	SIMS et al., Cloning the Interleukin 1 Receptor From Human T Cells, <i>Proc. Natl. Acad. Sci.</i> , 86:8946-8950 (1989)
	C138	SMITH et al., The Active Form of Tumor Necrosis Factor Is a Trimer, <i>J. Biol. Chem.</i> , 262:6951-6954 (1987)
	C139	SMITH et al., Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen, <i>Science</i> , 238:1704-1707 (1987)
	C140	SMITH et al., Multimeric Structure of the Tumor Necrosis Factor Receptor of HeLa Cells, <i>J. Biol. Chem.</i> , 264:14646-14652 (1989)
	C141	SPICER et al., Isolation of cDNA Clones Coding for Human Tissue Factor: Primary Structure of the Protein and cDNA, <i>Proc. Natl. Acad. Sci.</i> , 84:5148-5152 (1987)
	C142	STAINES et al., Collagen Arthritis-What Can It Teach Us?, <i>British Journal of Rheumatology</i> , 33:798-807 (1994)
	C143	STRADER et al., Structural Basis of β -Adrenergic Receptor Function, <i>The FASEB Journal</i> , 3:1825-1832 (1989)

Examiner
Signature

Date
Considered

3/11/02



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	8	of	8	Attorney Docket Number	01017/40451C

125	C144	SUGGS et al., Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β_2 -Microglobulin, Proc. Natl. Acad. Sci. U.S.A., 78:6613-6617 (1981)	
	C145	TAUBER et al., Toxicity in Neuronal Cells Caused by Cerebrospinal Fluid From Pneumococcal and Gram-Negative Meningitis, The Journal of Infectious Diseases, 166:1045-1050 (1992)	
	C146	THOMA et al., Identification of a 60-kD Tumor Necrosis Factor (TNF) Receptor as the Major Signal Transducing Component in TNF Responses, J. Exp. Med. 172: 1019-23 (1990)	
	C147	TSUJIMOTO et al., Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells, Archives of Biochemistry and Biophysics, 249:563-568 (1986)	
	C148	TSUJIMOTO et al., Interferon- γ Enhances Expression of Cellular Receptors for Tumor Necrosis Factor, J. Immunol., 136:2441-2444 (1986)	
	C149	TSUJIMOTO et al., Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells, Proc. Natl. Acad. Sci. 82: 7626-30 (1985)	
	C150	ULICH et al., Intratracheal Administration of Endotoxin and Cytokines, Clinical Immunology & Immunopathology, 72:137-140 (1994)	
	C151	UNGLAUB et al., Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators, J. Exp. Med. 166:1788-1797 (1987)	
	C152	VAN DER POLL et al., Pretreatment with a 55-kDa Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Attenuates Activation of Coagulation, but not of Fibrinolysis, during Lethal Bacteremia in Baboons, The Journal of Infectious Diseases., 176:296-299 (1997)	
	C153	VAN ZEE et al., Protection Against Lethal <i>Escherichia coli</i> Bacteremia in Baboons (<i>Papio anubis</i>) by Pretreatment With a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081, J. Immunol., 156:2221-2230 (1996)	
	C154	WALLACH et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Progress, Inflammation Research & Therapy, 51:57 (1991)	
	C155	WALLACH et al., Cell surface and soluble TNF receptors, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Nov. 21-25, 1990), Osawa and Bonavida, eds., Basel, Karger, pp 47-57 (1992).	
	C156	WILKS, The CD4 Receptor: Post Binding Events, Conformational Change and the Second Site, Molec. Aspects Med., 12:255-265 (1991)	
	C157	YAMASAKI et al., Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN β 2) Receptor, Science, 241:825-828 (1988).	
	C158	YONEHARA et al., A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated With the Receptor of Tumor Necrosis Factor, J. Exp. Med., 169:1747-1765 (1989)	
	C159	YOSHIE et al., Binding and Crosslinking of 125 I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors, J. Biochem., 100: 531-541(1986)	
	C160	BROWER et al. Roche's RA Drug Crippled, Nature Biotechnology, 15:1325 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/10/07
--------------------	--	-----------------	---------